CL2017002677A1 - Method to increase the percentage of monomeric fab-dsfv antibodies of multimeric species - Google Patents
Method to increase the percentage of monomeric fab-dsfv antibodies of multimeric speciesInfo
- Publication number
- CL2017002677A1 CL2017002677A1 CL2017002677A CL2017002677A CL2017002677A1 CL 2017002677 A1 CL2017002677 A1 CL 2017002677A1 CL 2017002677 A CL2017002677 A CL 2017002677A CL 2017002677 A CL2017002677 A CL 2017002677A CL 2017002677 A1 CL2017002677 A1 CL 2017002677A1
- Authority
- CL
- Chile
- Prior art keywords
- percentage
- increase
- multimeric species
- monomeric fab
- species
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
<p>LA PRESENTE INVENCIÓN PROPORCIONA UN MÉTODO PARA AUMENTAR EL PORCENTAJE DE MONÓMERO EN UNA COMPOSICIÓN DE MOLÉCULAS DE ANTICUERPO EXPRESADAS RECOMBINAITEMENTE QUE SE CARACTERIZAN PORQUE LA MOLÉCULA DE ANTICUERPO COMPRENDE AL MENOS UN EV CON ESPECIFICIDAD PARA UN ANTÍGENO DE INTERÉS QUE COMPRENDE UNA VH Y UNA VL EN LA QUE DICHOS VH Y VL ESTÁN CONECTADOS DIRECTA O INDIRECTAMENTE A TRAVÉS DE UNO O MÁS ENLACES Y SE ESTABILIZAN MEDIANTE UN ENLACE DISULFURO ENTRE ELLOS, DICHO MÉTODO COMPRENDE: A) UNA ETAPA DE CONVERSIÓN TÉRMICA DE MANTENER LA COMPOSICIÓN QUE COMPRENDE LA MOLÉCULA DE ANTICUERPO A UNA TEMPERATURA EN EL INTERVALO DE 30 A 60 C DURANTE UN PERÍODO DE AL MENOS 1 HORA, EN EL QUE LA ETAPA A) SE REALIZA EN LA PRESENCIA DE UN AGENTE REDUCTOR O DESPUÉS DEL TRATAMIENTO CON UN AGENTE REDUCTOR.</p><p> THE PRESENT INVENTION PROVIDES A METHOD FOR INCREASING THE PERCENTAGE OF MONOMER IN A COMPOSITION OF RECOMBINATELY EXHIBITED MOLECULES THAT ARE CHARACTERIZED BECAUSE THE ANTIBODY MOLECULE UNDERTAKES AT LEAST ONE EVENT FOR A SPECIES VL IN WHICH SUCH VH AND VL ARE DIRECTLY OR INDIRECTLY CONNECTED THROUGH ONE OR MORE LINKS AND STABILIZE THROUGH A DIFFERENT LINK BETWEEN THEM, SUCH METHOD OF CONVERSION THROUGH THE MERCHANGE COMPARTMENT OF THE COMMERCE ANTIBODY TO A TEMPERATURE IN THE INTERVAL FROM 30 TO 60 C FOR A PERIOD OF AT LEAST 1 HOUR, IN WHICH STAGE A) IS PERFORMED IN THE PRESENCE OF A REDUCING AGENT OR AFTER TREATMENT WITH A REDUCING AGENT. </p>
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1506869.5A GB201506869D0 (en) | 2015-04-22 | 2015-04-22 | Method |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2017002677A1 true CL2017002677A1 (en) | 2018-03-23 |
Family
ID=53299018
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2017002677A CL2017002677A1 (en) | 2015-04-22 | 2017-10-20 | Method to increase the percentage of monomeric fab-dsfv antibodies of multimeric species |
Country Status (16)
Country | Link |
---|---|
US (2) | US10829565B2 (en) |
EP (1) | EP3286220A1 (en) |
JP (1) | JP6901402B2 (en) |
KR (1) | KR20170138551A (en) |
CN (1) | CN107683290B (en) |
AU (1) | AU2016251960A1 (en) |
BR (1) | BR112017022472A2 (en) |
CA (1) | CA2983537A1 (en) |
CL (1) | CL2017002677A1 (en) |
CO (1) | CO2017010845A2 (en) |
EA (1) | EA201792325A1 (en) |
GB (1) | GB201506869D0 (en) |
IL (1) | IL255094A0 (en) |
MX (1) | MX2017013419A (en) |
SG (1) | SG11201708430VA (en) |
WO (1) | WO2016170137A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201223276D0 (en) * | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
GB201506868D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
GB201506869D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
CN110392695B (en) * | 2016-12-09 | 2021-02-02 | Ose免疫疗法 | Antibodies and polypeptides against CD127 |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
DK336987D0 (en) | 1987-07-01 | 1987-07-01 | Novo Industri As | immobilization |
US4877868A (en) | 1986-03-12 | 1989-10-31 | Neorx Corporation | Radionuclide antibody coupling |
GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
JP3771253B2 (en) | 1988-09-02 | 2006-04-26 | ダイアックス コープ. | Generation and selection of novel binding proteins |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
DK0710719T3 (en) | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Generation of xenogenic antibodies |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
DK0564531T3 (en) | 1990-12-03 | 1998-09-28 | Genentech Inc | Enrichment procedure for variant proteins with altered binding properties |
PT100379B (en) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | LIBRARIES OF HETERODYMERIC RECEPTORS USING FAGOMIDEOS |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
PT1024191E (en) | 1991-12-02 | 2008-12-22 | Medical Res Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
JPH09506262A (en) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | Method for producing specific antibody |
AU1736495A (en) | 1994-01-31 | 1995-08-15 | Trustees Of Boston University | Polyclonal antibody libraries |
FR2716640B1 (en) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Device for centering and blocking a workpiece with a view to running it in using an expansion lapper. |
US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
JP2978435B2 (en) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | Method for producing acryloxypropyl silane |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
GB0202633D0 (en) * | 2002-02-05 | 2002-03-20 | Delta Biotechnology Ltd | Stabilization of protein preparations |
JP4603894B2 (en) | 2002-12-03 | 2010-12-22 | ユセベ ファルマ ソシエテ アノニム | Assays to identify antibody producing cells |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
PL1644412T5 (en) | 2003-07-01 | 2019-01-31 | Ucb Biopharma Sprl | Modified antibody fab fragments |
GB0315450D0 (en) * | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
KR101370253B1 (en) | 2004-10-22 | 2014-03-05 | 암젠 인크 | Methods for refolding of recombinant antibodies |
GB0425534D0 (en) * | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Process for obtaining antibodies |
CN101583370A (en) * | 2005-09-27 | 2009-11-18 | 阿穆尼克斯公司 | Proteinaceous pharmaceuticals and uses thereof |
US20070212703A1 (en) | 2005-09-27 | 2007-09-13 | Stemmer Willem P | Proteinaceous pharmaceuticals and uses thereof |
GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
EP2014680A1 (en) | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
EP2195341B1 (en) | 2007-09-26 | 2017-03-22 | UCB Biopharma SPRL | Dual specificity antibody fusions |
US20090269343A1 (en) | 2008-04-11 | 2009-10-29 | Duke University | Dual Specific Immunotoxin for Brain Tumor Therapy |
CA2733782A1 (en) | 2008-08-14 | 2010-02-18 | Merck Sharp & Dohme Corp. | Methods for purifying antibodies using protein a affinity chromatography |
AU2009296708A1 (en) * | 2008-09-26 | 2010-04-01 | Merck Sharp & Dohme Corp. | High titer antibody production |
WO2010035012A1 (en) * | 2008-09-26 | 2010-04-01 | Ucb Pharma S.A. | Biological products |
PL2424889T3 (en) * | 2009-04-30 | 2016-01-29 | Ablynx Nv | Method for the production of domain antibodies |
EP2475682B1 (en) | 2009-09-10 | 2018-01-31 | UCB Biopharma SPRL | Multivalent antibodies |
GB201005063D0 (en) * | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
GB0920127D0 (en) | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
GB201001791D0 (en) * | 2010-02-03 | 2010-03-24 | Ucb Pharma Sa | Process for obtaining antibodies |
ES2717883T3 (en) | 2010-03-25 | 2019-06-26 | Ucb Biopharma Sprl | DVD-LG molecules stabilized with disulfide |
GB201005064D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
US9150663B2 (en) * | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
TWI586806B (en) * | 2010-04-23 | 2017-06-11 | 建南德克公司 | Production of heteromultimeric proteins |
WO2012140214A1 (en) | 2011-04-13 | 2012-10-18 | Biomay Ag | IMMUNOAFFINITY SEPARATION MATERIALS COMPRISING ANTI-IgE ANTIBODY DERIVATIVES |
EP3418306B1 (en) * | 2011-10-11 | 2023-12-06 | F. Hoffmann-La Roche AG | Improved assembly of bispecific antibodies |
UA112203C2 (en) | 2011-11-11 | 2016-08-10 | Юсб Фарма С.А. | Fusion protein of a biospecific antibody that binds to human OX40 and serum human albumin |
CA2856216C (en) | 2011-11-11 | 2021-01-12 | Ucb Pharma S.A. | Albumin binding antibodies and binding fragments thereof |
US20150031861A1 (en) | 2012-03-09 | 2015-01-29 | Ucl Business Plc | Chemical Modification of Antibodies |
GB201208370D0 (en) | 2012-05-14 | 2012-06-27 | Ucb Pharma Sa | Antibodies |
GB201223276D0 (en) * | 2012-12-21 | 2013-02-06 | Ucb Pharma Sa | Antibodies and methods of producing same |
BR112016006197B1 (en) * | 2013-09-27 | 2023-04-11 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR PRODUCING A BISPECIFIC POLYPEPTIDE ANTIBODY |
GB201411320D0 (en) | 2014-06-25 | 2014-08-06 | Ucb Biopharma Sprl | Antibody construct |
GB201506870D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
GB201506869D0 (en) * | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method |
GB201506868D0 (en) | 2015-04-22 | 2015-06-03 | Ucb Biopharma Sprl | Method for protein purification |
US10781250B2 (en) | 2015-08-17 | 2020-09-22 | Lupin Limited | Refolding process for antibody's fragments |
-
2015
- 2015-04-22 GB GBGB1506869.5A patent/GB201506869D0/en not_active Ceased
-
2016
- 2016-04-22 KR KR1020177033852A patent/KR20170138551A/en active Search and Examination
- 2016-04-22 BR BR112017022472A patent/BR112017022472A2/en active Search and Examination
- 2016-04-22 EA EA201792325A patent/EA201792325A1/en unknown
- 2016-04-22 AU AU2016251960A patent/AU2016251960A1/en not_active Abandoned
- 2016-04-22 WO PCT/EP2016/059050 patent/WO2016170137A1/en active Application Filing
- 2016-04-22 CN CN201680031354.XA patent/CN107683290B/en active Active
- 2016-04-22 JP JP2017555395A patent/JP6901402B2/en active Active
- 2016-04-22 SG SG11201708430VA patent/SG11201708430VA/en unknown
- 2016-04-22 US US15/568,018 patent/US10829565B2/en active Active
- 2016-04-22 MX MX2017013419A patent/MX2017013419A/en unknown
- 2016-04-22 EP EP16721103.6A patent/EP3286220A1/en active Pending
- 2016-04-22 CA CA2983537A patent/CA2983537A1/en active Pending
-
2017
- 2017-10-17 IL IL255094A patent/IL255094A0/en unknown
- 2017-10-20 CL CL2017002677A patent/CL2017002677A1/en unknown
- 2017-10-25 CO CONC2017/0010845A patent/CO2017010845A2/en unknown
-
2020
- 2020-10-23 US US17/078,130 patent/US11834514B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CO2017010845A2 (en) | 2018-03-20 |
KR20170138551A (en) | 2017-12-15 |
US20210079120A1 (en) | 2021-03-18 |
US20180142039A1 (en) | 2018-05-24 |
IL255094A0 (en) | 2017-12-31 |
SG11201708430VA (en) | 2017-11-29 |
EP3286220A1 (en) | 2018-02-28 |
WO2016170137A1 (en) | 2016-10-27 |
CN107683290B (en) | 2022-01-04 |
JP2018515453A (en) | 2018-06-14 |
EA201792325A1 (en) | 2018-04-30 |
JP6901402B2 (en) | 2021-07-14 |
AU2016251960A1 (en) | 2017-11-02 |
CA2983537A1 (en) | 2016-10-27 |
CN107683290A (en) | 2018-02-09 |
US11834514B2 (en) | 2023-12-05 |
MX2017013419A (en) | 2018-02-09 |
US10829565B2 (en) | 2020-11-10 |
BR112017022472A2 (en) | 2018-07-17 |
GB201506869D0 (en) | 2015-06-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017002677A1 (en) | Method to increase the percentage of monomeric fab-dsfv antibodies of multimeric species | |
PE20170665A1 (en) | HUMANIZED ANTI-TAU ANTIBODIES | |
AR113342A1 (en) | CD47 / PD-L1 SPECIFIC ANTIBODIES | |
EA201790377A1 (en) | ANTIBODIES TO GLUCAGON AND THEIR APPLICATIONS | |
PE20180499A1 (en) | UNION TO TAU ANTIBODIES | |
AR096617A1 (en) | ANTI-TWEAKR ANTIBODIES AND THEIR USES | |
CU24597B1 (en) | HETERODIMERIC BIESPECIFIC ANTIBODIES THAT BIND CD3 AND CD20 | |
EA201890453A1 (en) | ANTI-ANGPTL8 ANTIBODIES AND THEIR APPLICATION | |
EA201890285A1 (en) | ANTIBODIES AGAINST PD-1, ACTIVATED ANTIBODIES AGAINST PD-1 AND METHODS OF THEIR APPLICATION | |
PH12018500707A1 (en) | Anti-human cd19 antibodies with high affinity | |
AR102239A1 (en) | ANTI-OX40 HUMANIZED ANTIBODIES AND THEIR USES | |
CO2017009060A2 (en) | Hybrid polypeptide of the immunoglobulin degradation enzyme g of s. pyogenes and immunoglobulin g degradation enzyme of streptococcus equi ssp. zooepidemicus | |
CO2017005738A2 (en) | Anti-pd-1 antibodies | |
PE20181018A1 (en) | NOVELTY ANTI-PD-1 ANTIBODIES | |
EA201491569A1 (en) | MODIFIED BISPECIFIC IgG4 ANTIBODIES WITH SYMMETRIC SEQUENCE | |
PE20181805A1 (en) | COMPOSITIONS AND ANTI-TIM-3 ANTIBODIES | |
CL2017002676A1 (en) | Monomerization method of recombinant antibody molecules | |
TR201901445T4 (en) | Il2rbeta / common gamma chain antibodies. | |
JO3532B1 (en) | Anti-il-33 antibodies and uses thereof | |
BR112019001138A2 (en) | bispecific proteins and methods for preparing them | |
EA201690167A1 (en) | HUMANIZED OR CHEMICAL ANTIBODIES TO CD3 | |
EA201891732A1 (en) | BISPECIFIC BINDING PROTEINS FOR PD-L1 AND KDR | |
EA201491571A1 (en) | MODIFIED BISPECIFIC IgG4 ANTIBODIES WITH ASYMMETRIC SEQUENCE | |
EA201591113A1 (en) | ANTIBODIES AGAINST ANTIGEN 2 BLOOD DENDRITIC CELLS AND THEIR APPLICATION | |
BR112014026740A2 (en) | antibody, composition, methods for treating a mammal and for providing an enhanced adcc antibody, and use of an antibody |